≡ Risteys
R13

Documentation Changelog GitHub Contact & Feedback

Granulosa cell carcinoma of ovary

Endpoint Browser PheWeb

C3_OVARY_GRANULOSA

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519972

1. Apply sex-specific rule

only females

293218

2. Check conditions

None

293218

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Cancer registry: Topography ICD-O-3 — C56
  • Cancer registry: Morphology ICD-O-3 — 8620
  • Cancer registry: Behaviour codes — 3

1 out of 7 registries used, show all original rules.

150

4. Check minimum number of events

None

150

5. Include endpoints

None

150

6. Filter based on genotype QC (FinnGen only)

142

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

First used in FinnGen datafreeze
DF9

Case counts by codes

↥

FinnGen case counts by registry codes:

Not enough data for upset plot.

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 142 142 -
Unadjusted period prevalence (%) 0.05 0.05 -
Median age at first event (years) 55.23 55.23 -

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
150
Matched controls
1500
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8620/3-C56.9
ICD-O-3
Adult granulosa cell tumor of ovary of ovary
+∞
216.8
150
*
C56.92
ICD-10 Finland
Malignant ovarian tumor, sex chord stroma derived
+∞
162.5
125
*
D39.10
ICD-10 Finland
Tumor of uncertain or unknown nature in the ovary without histology
107.3
144.2
78
15
LAF11
NOMESCO Finland
Laparoscopic bilateral salpingo-oophorectomy
23.5
65.7
54
35
LX1XE
NOMESCO Finland
Other gynecological ultrasound examination
31.2
64.8
46
21
JN4BD
NOMESCO Finland
Extensive body CT
26.9
62.2
47
25
B01AB10
ATC
tinzaparin; parenteral
14.7
54.4
61
67
128
Kela drug reimbursment
Cancers of female genital organs
+∞
41.6
38
*
C56.91
ICD-10 Finland
Malignant granulosa cell tumor in ovary
+∞
39.3
36
*
JAL31
NOMESCO Finland
Laparoscopic omentectomy
+∞
32.5
30
*
H02AB02
ATC
dexamethasone; systemic
52.0
30.6
36
9
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
9.7
29.6
40
54
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
6.8
28.0
59
130
JAL30
NOMESCO Finland
Omentectomy
64.5
27.4
31
6
JAL00
NOMESCO Finland
Biopsy of peritoneum
113.9
26.7
28
*
B01AB05
ATC
enoxaparin; parenteral
5.9
26.6
89
296
WX302
NOMESCO Finland
Thoracal epidural anesthesy
33.3
26.3
34
13
LCD04
NOMESCO Finland
Laparoscopic hysterectomy
10.4
25.9
32
38
LC2BE
NOMESCO Finland
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
6.0
25.2
103
401
JEA00
NOMESCO Finland
Appendectomy
10.7
24.1
29
33
WX404
NOMESCO Finland
Intravenous generell anesthesy
5.3
21.4
62
177
L02BG04
ATC
letrozole; oral
56.6
20.9
24
5
LCD00
NOMESCO Finland
Hysterectomy
7.7
20.7
33
53
LAF16
NOMESCO Finland
Excision of uterus, adnexes and lymph nodes for treatment of ovarian cancer
+∞
20.3
19
*
R19.0
ICD-10 Finland
Intra-abdominal and pelvic swelling, mass and lump
20.8
19.7
29
17
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
19.2
18
*
XLD00
NOMESCO Finland
Sytologyspecimen from mouth of uterus
5.0
18.3
51
139
C56.00
ICD-10 Finland
Malignant tumor of the ovary without histology
+∞
18.1
17
*
A04AA01
ATC
ondansetron; systemic, rectal
16.9
17.7
28
20
LAF10
NOMESCO Finland
Bilateral salpingo-oophorectomy
15.3
17.6
29
23
L03AA13
ATC
pegfilgrastim; parenteral
+∞
17.0
16
*
JAL01
NOMESCO Finland
Laparoscopic biopsy of peritoneum
+∞
17.0
16
*
WX402
NOMESCO Finland
General anaesthesia
4.8
16.8
49
138
LC2AE
NOMESCO Finland
Ultrasound examination of uterus and parametria
5.0
16.6
45
119
LCD01
NOMESCO Finland
Total laparoscopic hysterectomy
18.5
16.4
25
16
LC2DE
NOMESCO Finland
Demanding ultrsound examination of uterus, parametrium and lower part of abdomen with speciel methods
8.3
16.2
23
32
JAL20
NOMESCO Finland
Excision or destruction of lesion of peritoneum
67.6
16.1
18
*
LAF01
NOMESCO Finland
Laparoscopic unilateral salpingo-oophorectomy
13.0
15.8
28
26
ZX120
NOMESCO Finland
Intravenous
8.1
15.7
23
33
ZXE10
NOMESCO Finland
More than one and less than three hours
3.9
15.5
82
353
TPH07
NOMESCO Finland
Cathetrisation of artery
6.2
15.1
29
56
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
17.8
15.0
23
15
JAP00
NOMESCO Finland
Freeing of adhesions in the peritoneal cavity
40.5
14.8
18
5
JN4AD
NOMESCO Finland
Body CT examination
11.9
14.7
27
27
ZXE20
NOMESCO Finland
More than three and less than five hours
5.1
14.4
36
88
A03FA01
ATC
metoclopramide; systemic, rectal
4.2
14.2
49
155
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
11.8
14.2
26
26
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
13.7
13
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
13.7
13
*
A04AA02
ATC
granisetron; systemic, transdermal
153.3
13.7
14
*
L02AB02
ATC
medroxyprogesterone; systemic
44.3
13.4
16
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
12.7
12
*
115
Kela drug reimbursment
Breast cancer
+∞
12.7
12
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
141.3
12.6
13
*
HA1AA
NOMESCO Finland
X-ray mammography
10.4
12.3
24
27
R2110
NOMESCO Finland
Giving the first information
5.3
11.7
26
57
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
+∞
11.6
11
*
WC125
NOMESCO Finland
Demanding cytostatic therapy of local tumor recidive
+∞
11.6
11
*
L02BA01
ATC
tamoxifen; oral
+∞
11.6
11
*
C56.98
ICD-10 Finland
Malignant tumor of the ovary, indeterminate histology
+∞
11.6
11
*
LAF00
NOMESCO Finland
Unilateral salpingo-oophorectomy
15.8
10.8
17
12
L03AA14
ATC
lipegfilgrastim; parenteral
+∞
10.5
10
*
ZXD10
NOMESCO Finland
Scheduled procedure
3.0
10.2
79
402
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
+∞
9.5
9
*
WC115
NOMESCO Finland
Cytostatic therapy of local tumor recidive with multiple drugs
+∞
9.5
9
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
+∞
9.5
9
*
C78.6
ICD-10 Finland
Secondary malignant neoplasm of retroperitoneum and peritoneum
+∞
9.5
9
*
D39.13
ICD-10 Finland
Uncertain growth nature of the ovarian tumor, sex chord derived
+∞
9.5
9
*
JAH00
NOMESCO Finland
Laparotomy
17.0
9.2
14
9
LCA06
NOMESCO Finland
Biopsy of endometrium
3.3
8.9
43
165
D39.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Uterus
95.2
8.5
9
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
8.4
8
*
A04AD12
ATC
aprepitant; systemic
+∞
8.4
8
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
8.4
8
*
D39.12
ICD-10 Finland
Granulosa cell tumor of uncertain nature in the ovary
+∞
7.3
7
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
7.3
7
*
JAW96
NOMESCO Finland
Other operation on abdominal wall, peritoneum, mesentery or omentum
+∞
7.3
7
*
L03AA02
ATC
filgrastim; parenteral
+∞
7.3
7
*
HAC20
NOMESCO Finland
Total mastectomy
+∞
7.3
7
*
D39.19
ICD-10 Finland
Tumor of uncertain or unknown nature in the ovary with unspecified histology
31.7
7.2
9
*
WZC00
NOMESCO Finland
Treatment plan or consultation
2.6
7.2
61
313
TPX10
NOMESCO Finland
Implantation of vascular injection port
14.7
7.0
11
8
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
10.0
6.9
13
14
WX408
NOMESCO Finland
General anesthesy, balanced
2.7
6.9
49
230
WW500
NOMESCO Finland
Blood transfusion
17.7
6.8
10
6
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
6.3
6
*
1830A
ICD-9 Finland
Malignant neoplasm of ovary and other uterine adnexa, Ovary
+∞
6.3
6
*
A04AA03
ATC
tropisetron; systemic
+∞
6.3
6
*
C56
ICD-10 Finland
Malignant neoplasm of ovary
+∞
6.3
6
*
D27.93
ICD-10 Finland
Benign ovarian tumor, sex chord stroma derived
+∞
6.3
6
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
6.3
6
*
N83.2
ICD-10 Finland
Other and unspecified ovarian cysts
2.9
6.3
34
138
N95.0
ICD-10 Finland
Postmenopausal bleeding
3.0
6.1
31
121
121
Kela drug reimbursment
Severe hypofunction of sexual glands
7.8
6.1
13
18

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
125
0
+∞
162.53
9.4
0.0
143.19
—
ng/l
—
74
0
54
36
22.88
64.75
1.3
1.4
—
—
—
0
0
45
8
79.41
41.08
1.1
1.0
—
—
—
0
0
36
56
8.14
23.38
1.3
1.7
6.62
2.19
ug/l
0.50
24
41
34
65
6.47
18.00
2.5
1.3
30.71
25.68
iu/l
0.41
28
59
77
305
4.13
16.65
2.0
1.8
—
—
—
0
0
41
100
5.27
16.65
1.2
1.1
—
—
—
0
0
102
509
4.14
15.44
2.7
2.1
—
—
—
0
0
89
467
3.23
11.21
2.7
1.6
—
—
—
0
0
9
0
+∞
9.47
1.3
0.0
13.67
—
u/ml
—
9
0
14
33
4.57
4.45
1.9
1.9
38.20
223.06
u/l
—
5
9
92
657
2.04
4.25
10.2
6.7
3.52
3.89
e9/l
1.54
81
582
49
281
2.10
4.13
6.3
5.1
—
—
—
0
0
90
645
1.99
4.03
3.1
3.4
0.00
0.03
estimate
0.50
19
111
89
642
1.95
3.84
3.6
4.6
0.00
0.00
estimate
-0.00
18
113
62
407
1.89
3.47
2.4
3.5
62.46
119.38
e6/l
0.72
41
271
12
34
3.74
3.28
2.1
1.9
21.33
21.36
s
0.00
12
28
47
298
1.84
2.84
1.4
1.4
—
—
—
0
0
8
18
4.63
2.83
1.4
1.1
—
—
—
0
0
42
258
1.87
2.80
1.8
1.7
1.11
0.89
mg/l
0.39
37
206
46
291
1.84
2.80
2.1
2.7
0.36
0.45
e6/l
0.23
32
215
46
292
1.83
2.76
2.1
2.6
—
—
—
0
0
48
319
1.74
2.44
2.0
2.8
48.33
86.66
e6/l
0.32
35
242
55
386
1.67
2.28
2.6
1.9
2.37
2.35
mmol/l
0.42
50
328
13
56
2.45
2.11
4.6
4.2
—
—
—
0
0
123
1343
0.53
2.11
4.5
4.9
2.82
2.89
mmol/l
0.48
115
1247
18
92
2.09
2.00
8.9
4.4
105.28
103.93
mmol/l
0.61
18
92
11
46
2.50
1.90
12.1
6.0
1.25
1.48
%
0.44
11
46
11
46
2.50
1.90
12.0
6.0
0.80
0.68
%
0.42
11
46
142
1321
2.40
1.85
15.3
11.0
139.89
139.98
mmol/l
0.17
142
1280
114
1261
0.60
1.80
3.8
4.0
1.35
1.25
mmol/l
0.76
107
1163
115
1269
0.60
1.79
4.4
5.0
1.98
2.79
mu/l
0.40
109
1174
106
916
1.54
1.58
7.3
4.9
76.35
76.57
u/l
0.03
100
830
53
400
1.50
1.52
2.2
2.6
—
—
—
0
0
9
177
0.48
1.52
1.6
1.2
—
—
—
0
0
9
37
2.52
1.51
4.8
4.4
—
—
—
0
0
111
1223
0.64
1.48
4.6
5.4
39.52
39.22
mmol/mol
0.12
103
1143
68
543
1.46
1.47
6.9
4.7
1.20
1.23
mmol/l
1.73
63
476
60
472
1.45
1.38
16.9
10.2
1.15
1.18
inr
0.09
20
142
6
132
0.43
1.36
1.3
1.3
—
—
—
0
0
45
336
1.48
1.35
3.8
3.7
0.00
0.00
estimate
-0.00
18
114
0
40
0.00
1.35
0.0
4.0
—
—
—
0
0
101
879
1.46
1.33
3.4
3.2
—
—
—
0
0
123
1318
0.63
1.27
4.1
4.5
4.88
4.92
mmol/l
0.17
116
1231
12
63
1.98
1.27
12.0
5.1
—
—
—
0
0
6
26
2.36
1.20
1.7
2.6
—
—
—
0
0
6
26
2.36
1.20
3.8
4.5
3.93
3.73
mmol/l
—
6
26
136
1271
1.75
1.18
12.1
9.6
25.91
18.08
mg/l
1.97
113
937
87
987
0.72
1.16
3.8
4.0
9.95
11.37
mm/h
0.80
82
890
23
153
1.59
1.15
1.7
2.8
4.60
4.42
e6/l
0.03
11
75
18
114
1.66
1.08
1.4
1.5
—
—
—
0
0
5
106
0.45
1.06
3.2
2.4
1.82
1.53
%
—
5
97
39
297
1.42
1.04
3.4
3.3
—
—
—
0
0
123
1309
0.66
1.04
4.0
4.4
1.55
1.61
mmol/l
0.86
116
1219
5
22
2.31
1.04
1.6
1.2
—
—
—
0
0
25
341
0.68
0.96
1.4
1.3
1.91
1.59
u/ml
—
7
106
7
129
0.52
0.93
1.4
1.4
—
—
—
0
0
120
1107
1.42
0.93
18.5
13.4
331.14
330.92
g/l
0.11
120
1100
40
499
0.73
0.92
1.6
1.9
88.83
99.49
pmol/l
0.76
16
225
8
45
1.82
0.86
16.9
5.1
—
—
—
0
0
0
24
0.00
0.80
0.0
1.1
—
—
—
0
0
99
900
1.29
0.75
3.6
3.8
—
—
—
0
0
73
639
1.28
0.75
3.3
3.4
0.00
0.00
estimate
-0.00
19
122
5
25
2.03
0.73
1.2
1.1
—
—
—
0
0
124
1300
0.73
0.66
3.9
4.4
5.73
5.82
mmol/l
0.47
115
1193
6
102
0.57
0.65
2.3
1.4
—
—
—
0
0
7
111
0.61
0.61
1.0
1.2
—
—
—
0
0
0
21
0.00
0.60
0.0
1.2
—
—
—
0
0
10
64
1.60
0.60
2.4
2.3
4.42
4.36
kpa
—
10
64
32
387
0.78
0.57
2.8
3.6
7.64
5.90
mg/mmol
0.10
19
208
60
528
1.23
0.55
7.8
7.4
0.00
0.00
e9/l
0.50
50
434
6
39
1.56
0.53
18.3
5.5
23.18
24.65
mmol/l
—
6
39
7
45
1.58
0.49
8.1
4.0
22.06
25.63
mmol/l
—
7
45
7
47
1.51
0.48
1.6
1.2
—
—
—
0
0
11
152
0.70
0.47
1.4
1.3
—
—
—
0
0
103
1087
0.83
0.43
3.8
4.2
14.60
14.59
pmol/l
0.02
96
1000
32
375
0.81
0.43
2.4
3.1
2407.03
435.79
mg/l
0.37
19
213
12
88
1.40
0.41
4.7
3.1
—
—
—
0
0
5
35
1.44
0.39
1.4
3.5
20.84
24.34
mmol/l
—
5
35
8
113
0.69
0.39
1.3
1.2
—
—
—
0
0
139
1355
1.35
0.36
13.7
9.3
—
—
—
0
0
11
82
1.37
0.35
2.4
3.0
5.99
5.90
kpa
0.08
11
82
37
325
1.18
0.34
4.1
2.6
7.41
7.40
ph
—
5
46
11
83
1.35
0.33
2.3
2.9
1.11
2.47
mmol/l
0.35
11
69
6
47
1.29
0.32
1.7
2.2
0.62
0.69
%
—
6
47
30
342
0.85
0.30
3.3
3.1
—
—
—
0
0
34
383
0.85
0.30
1.6
1.6
1.19
1.40
mmol/l
1.28
29
331
12
151
0.78
0.30
2.4
2.3
13.34
14.20
umol/l
0.17
12
142
12
94
1.30
0.29
4.5
3.0
—
—
—
0
0
8
63
1.28
0.28
1.8
1.3
—
—
—
0
0
5
73
0.67
0.26
10.2
2.4
1.23
1.24
mmol/l
—
5
61
39
356
1.13
0.22
2.6
3.0
—
—
—
0
0
5
41
1.23
0.22
1.2
1.2
—
—
—
0
0
12
145
0.81
0.22
2.0
1.8
—
—
—
0
0
8
105
0.75
0.21
1.3
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.9
—
—
—
0
0
0
14
0.00
0.20
0.0
1.9
—
105.29
—
0
14
0
14
0.00
0.20
0.0
1.9
—
3.95
—
0
14
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
6
49
1.23
0.20
3.2
2.1
1.20
1.11
%
—
6
49
10
122
0.81
0.20
2.7
2.5
18.97
23.65
%
—
10
107
16
137
1.19
0.19
1.1
1.3
—
—
—
0
0
6
52
1.16
0.19
3.0
2.4
26.58
25.58
mmol/l
—
6
52
19
166
1.17
0.19
1.9
1.5
—
—
—
0
0
5
66
0.75
0.17
1.2
1.1
—
—
—
0
0
6
75
0.79
0.16
1.0
1.4
—
—
—
0
0
14
121
1.17
0.15
1.8
1.4
—
—
—
0
0
9
82
1.10
0.15
2.6
2.2
—
—
—
0
0
9
105
0.85
0.13
1.3
1.3
—
—
—
0
0
9
109
0.81
0.13
1.4
1.5
—
—
—
0
0
40
424
0.92
0.13
3.1
3.2
25.36
16.80
ng/l
0.30
28
264
66
635
1.07
0.12
3.8
5.8
0.18
0.18
e9/l
0.07
57
565
13
115
1.14
0.11
1.8
1.7
371.92
338.26
nmol/l
0.39
13
107
24
223
1.09
0.10
7.6
3.2
—
—
—
0
0
18
196
0.91
0.09
1.8
1.8
—
—
—
0
0
5
62
0.80
0.08
1.8
1.8
—
—
—
0
0
7
63
1.12
0.08
2.7
2.5
—
—
—
0
0
27
286
0.93
0.08
1.4
1.3
14.38
41.21
iu/ml
—
8
100
12
108
1.12
0.07
2.6
3.4
—
—
—
0
0
27
285
0.94
0.07
1.4
1.3
2.31
12.10
u/ml
2.06
12
119
9
87
1.04
0.07
1.4
1.2
—
—
—
0
0
63
613
1.05
0.07
3.9
5.4
0.04
0.04
e9/l
0.01
54
535
64
626
1.04
0.05
3.9
5.4
1.81
1.90
e9/l
0.47
57
560
62
609
1.03
0.03
3.9
5.4
0.48
0.54
e9/l
1.87
54
534
19
199
0.95
0.03
2.2
1.4
1424.00
599.22
titre
—
5
51
14
139
1.01
0.00
1.4
1.6
—
—
—
0
0
28
277
1.01
0.00
1.4
1.3
2.44
2.38
g/l
0.09
18
157
11
105
1.05
0.00
1.1
1.3
—
33.36
—
0
5
56
564
0.99
0.00
5.0
5.9
—
—
—
0
0
48
484
0.99
0.00
2.4
2.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
82.39
—
0
7
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
9.3
—
0.68
—
0
8
0
8
0.00
0.00
0.0
3.6
—
9.13
—
0
8
0
5
0.00
0.00
0.0
2.6
—
10.58
—
0
5
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
0.99
—
0
8
0
5
0.00
0.00
0.0
1.4
—
79.18
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
5.4
—
—
—
0
0
5
50
1.00
-0.00
10.8
6.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
11.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
1.05
—
0
6
8
85
0.94
-0.00
1.5
2.0
4.26
3.96
e9/l
—
8
66
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
5.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.9
—
64.33
—
0
9
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
6
67
0.89
-0.00
12.8
5.9
11.97
9.23
mmol/l
—
6
61
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
1.47
—
0
6
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
1.79
—
0
9

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: C3_OVARY_GRANULOSA – Granulosa cell carcinoma of ovary

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).